The Residual Risk Odyssey: From LDL to Lp(a)
- PMID: 34325832
- DOI: 10.1016/j.jacc.2021.04.103
The Residual Risk Odyssey: From LDL to Lp(a)
Keywords: PCSK9 inhibitor; acute coronary syndrome; lipoprotein(a); low-density lipoprotein cholesterol.
Conflict of interest statement
Funding Support and Author Disclosures Dr Rosenson has received research funding to his institution from Amgen, the National Institutes of Health, Novartis, and Regeneron; has received consulting fees from Amgen, C5, CVS Caremark, The Medicines Company, Regeneron, and 89Bio; has received nonpromotional speaking fees from Amgen, Kowa, and Regeneron; has received royalties from Wolters Kluwer (UpToDate); and has stock holdings in MediMergent. Dr Goonewardena has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous